COMT gene and risk for Parkinson's disease: A systematic review and meta-analysis

Pharmacogenetics and Genomics

Volumn 24, Issue 7, 2014, Pages 331-339

  Jiménez Jiménez, Félix J ^a,b   Alonso Navarro, Hortensia ^a   García Martín, Elena ^c   Agúndez, José A G ^c  

^a Uro Ginecológico   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

COMT polymorphisms; genetics; meta analysis; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ALLELE; COGNITIVE DEFECT; COMPUTER PROGRAM; DAYTIME SOMNOLENCE; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; IMPULSE CONTROL DISORDER; META ANALYSIS; NEUROIMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MODELS, GENETIC; ODDS RATIO; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84902247777     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000056     Document Type: Review

References (59)

1. Agúndez JA, García-Martín E, Alonso-Navarro H, Jiménez-Jiménez FJ. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 2013; 9: 859-874.
2. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound cathechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
3. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A, et al. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996; 228: 780-784.
4. Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997; 7: 65-71.
5. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, et al. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997; 221: 202-204.
6. Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol- Omethyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997; 12: 426-427.
7. Yoritaka A, Hattori N, Yoshino H, Mizuno Y. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication. J Neural Transm 1997; 104: 1313-1317.
8. Mizuta I, Mizuta E, Yamasaki S, Kuno S, Yasuda M, Tanaka C. Metaanalysis of polymorphism of the catechol-O-methyltransferase gene in relation to the etiology of Parkinson's disease in Japan. Mov Disord 2000; 15: 1013-1014.
9. Lee MS, Lyoo CH, Ulmanen I, Syvänen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001; 298: 131-134.
10. Wu RM, Cheng CW, Chen KH, Lu SL, Shan DE, Ho YF, Chern HD. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. Neurology 2001; 56: 375-382.
11. Hernán MA, Checkoway H, O'Brien R, Costa-Mallen P, De Vivo I, Colditz GA, et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 2002; 58: 1381-1387.
12. Eerola J, Launes J, Hellström O, Tienari PJ, Apolipoprotein E. (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci Lett 2002; 330: 296-298.
13. Goudreau JL, Maraganore DM, Farrer MJ, Lesnick TG, Singleton AB, Bower JH, et al. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Mov Disord 2002; 17: 1305-1311.
14. Xu L, Hao YX, Xie HJ, Tang GM, Ren DP. Catecholamine-Omethyltransferase (COMT) gene polymorphism and the risk of Parkinson's disease in Shanghai Han population. Chin J Med Genet 2002; 19: 440-441.
15. Lynch DR, Mozley PD, Sokol S, Maas NM, Balcer LJ, Siderowf AD. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord 2003; 18: 804-812.
16. Watanabe M, Harada S, Nakamura T, Ohkoshi N, Yoshizawa K, Hayashi A, Shoji S. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003; 48: 190-193.
17. Ming S, Zuolin L, Enxiang T, Biao C. Correlation between the genetic polymorphism of dopamine metabolic enzymes and the genetic susceptibility of Parkinson's disease. J Gerontol 2005; 25: 743-745.
18. Kalinderi K, Fidani L, Kourtesi G, Katsarou Z, Mioglou E, Bostantjopoulou S. No association of the Val158Met COMT polymorphism with Parkinson's disease in the Greek population. Eur J Neurol 2008; 15:e83.
19. Białecka M, Kurzawski M, Kłodowska-Duda G, Opala G, Tan EK, Droździk M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008; 18: 815-821.
20. Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, Owen AM. The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiol Aging 2010; 31: 1064-1068.
21. Punia S, Das M, Behari M, Mishra BK, Sahani AK, Govindappa ST, et al. Role of polymorphisms in dopamine synthesis and metabolism genes and association of DBH haplotypes with Parkinson's disease among North Indians. Pharmacogenet Genomics 2010; 20: 435-441.
22. Benitez BA, Forero DA, Arboleda GH, Granados LA, Yunis JJ, Fernandez W, Arboleda H. Exploration of genetic susceptibility factors for Parkinson's disease in a South American sample. J Genet 2010; 89: 229-232.
23. Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, et al. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population. BMC Neurol 2011; 11:89.
24. Torkaman-Boutorabi A, Ali Shahidi G, Choopani S, Reza Zarrindast M. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population. Folia Neuropathol 2012; 50: 382-389.
25. Shih PY, Tze-Kiong ER, Shang JG. An association study between genetic variants at mu-opioid receptor, dopamine transporter, catechol- Omethyltransferase, and dopamine genes and risk of Parkinson's disease. Neurol Asia 2013; 18: 279-287.
26. Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, et al. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 2013; 84: 666-673.
27. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N, Inoko H. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 2003; 250 (Suppl 3):III40-III43.
28. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies. J Natl Cancer Inst 1959; 22: 719-748.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
31. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
33. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002; 51: 133-136.
34. Zhao X, Xie H, Tang G, Zhao W, Xü L, Lin D, et al. Association between four genes involved in dopaminergic neurotransmitter metabolism COMT, DBH, DAT1, MAOB and susceptibility to Parkinson's disease in Shanghai Hans. Chin J Clin Rehabil 2003; 7: 1126-1127.
35. Białecka M, Droździk M, Honczarenko K, Gawrońska- Szklarz B, Stankiewicz J, Dabrowska E, et al. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol 2005; 53: 68-73.
36. Maraganore DM, de Andrade M, Lesnick G, Strain KJ, Farrer MJ, Rocca WA, et al. High-Resolution Whole-Genome Association study or Parkinson disease. Am J Hum Genet 2005; 77: 685-693.
37. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzukin S, Momose Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006; 15: 1151-1158.
38. Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, Britton A, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006; 5: 911-916.
39. Białecka M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, Safranow K, Droździk M. Polymorphisms of catechol-Omethyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 224-229.
40. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories: genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009; 124: 593-605.
41. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genomewide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
42. Gu Z, Feng X, Dong X, Chan P. Smoking, genes encoding dopamine pathway and risk for Parkinson's disease. Neurosci Lett 2010; 482: 31-34.
43. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143-148.
44. Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic- pharmacodynamic pattern in patients with Parkinson's disease. Mov Disord 2005; 20: 734-739.
45. de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ. Catechol-Omethyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov Disord 2012; 27: 132-135.
46. Białecka M, Droździk M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, Stankiewicz J. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004; 110: 260-266.
47. Torkaman-Boutorabi A, Shahidi GA, Choopani S, Rezvani M, Pourkosary K, Golkar M, Zarrindast MR. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. Acta Neurobiol Exp (Wars) 2012; 72: 272-282.
48. Tan EK, Cheah SY, Fook-Chong S, Yew K, Chandran VR, Lum SY, Yi Z. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 137B: 1-4.
49. Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002; 58: 564-567.
50. Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011; 69: 111-118.
51. Rissling I, Frauscher B, Kronenberg F, Tafti M, Stiasny-Kolster K, Robyr AC, et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep 2006; 29: 108-111.
52. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012; 18: 397-399.
53. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007; 27: 4832-4838.
54. Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, et al. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain 2012; 135: 2449-2457.
55. Hoogland J, de Bie RM, Williams-Gray CH, Muslimović D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010; 25: 2550-2554.
56. Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet Genomics 2012; 22: 716-724.
57. Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012; 27: 512-518.
58. Wang Y, Yang X. Association of catechol-O-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis. J Mot Behav 2012; 44: 365-372.
59. Lechun L, Yu S, Pengling H, Changgi H. The COMT Val158Met polymorphism as an associated risk factor for Parkinson's disease in Asian rather than Caucasian populations. Neurol India 2013; 61: 12-16.